Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th ...

We evaluated the effects of digital health technologies (DHTs) on women's health, empowerment, and gender equality, using the ...

“DA POPE!” blared the front of the Chicago Sun-Times on Friday, one of countless spins on the city’s unique accent, ...

As a dietitian who’s reviewed and tested dozens—if not hundreds—of products, I can confidently say supplements can make a ...

Turmeric and black pepper have a synergistic relationship. Learn how to use them together to increase turmeric’s ...

Yolanda Tillman, 42, has been sentenced to 9 years for her involvement in a cocaine distribution network and will also serve ...

Q1 2025 Earnings Call Transcript May 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $2.7, ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall ...

Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the first quarter ended March 28, ...

Adding protein to your meals helps with weight loss by increasing your satiety, reducing appetite, boosting metabolism, and ...